Memary, an N-methyl-D-aspartate (NMDA) receptor antagonist, is the generic version of Memantine Hydrochloride, which was licensed from Merz Pharmaceuticals.
Daiichi Sankyo has obtained the Japanese approval to manufacture and market Memary 5mg, 10mg and 20mg Tablets on 21 January 2011.
The drug was approved for use in the treatment of patients with AD by the European EMEA in 2002 and by the US Food and Drug Administration in 2003.